FDA approves first and only tardive dyskinesia treatment
April 12, 2017Research and Development, Sales and Marketing FDA, Neurocrine Biosciences, tardive dyskinesia
US patients suffering with tardive dyskinesia (TD) will see access to the first approved treatment in the country with the …
Komodo dragon blood could hold secret to new antibiotic
April 12, 2017Research and Development Antibiotics, Komodo dragon, antibiotic resistance
The urgency to find new antibiotics has led researchers into the mouths of Komodo dragons. In particular, the researchers were …
Huge doses of vitamin C found to boost cancer treatment
April 12, 2017Research and Development Cancer, Vitamin c
It may sound like the kind of science that would raise eyebrows rather than scientific interest but recent research has …
e-Therapeutics installs new CEO in position
April 11, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing e-Therapeutics
e-Therapeutics, a drug discovery company, announced that Dr. Raymond Barlow assumed the position of CEO at the beginning of April. …
Trials and Tribulations: The impact of new clinical trial regulation in Europe
April 11, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EU, UK, brexit, clinical trials, regulations
The clinical trial is the fulcrum on which drug development and treatment hinges. Even with the advent of new technologies …
Hilleman labs partners with Indian Government for shigella vaccine
April 11, 2017Manufacturing and Production, Sales and Marketing NICED, hilleman, shigella
India’s Hilleman Laboratories and the National Institute of Cholera and Enteric Diseases (NICED) are set to develop and market a …
J&J acquires Neuravi to bolster neuro business
April 11, 2017Manufacturing and Production, Sales and Marketing Johnson & Johnson, Neuravi
Johnson & Johnson’s neurosurgery and neurovascular unit, Codman Neuro, has made the move to acquire Galway-based company, Neuravi. The exact …
Scotland recommends Janssen’s Imbruvica for leukaemia
April 11, 2017Manufacturing and Production, Sales and Marketing SMC, imbruvica, leukaemia
Janssen has been celebrating the news that its Imbruvica (ibrutinib) has been recommended by the Scottish Medicines Consortium (SMC) for …
Egypt and India ties in pharmaceuticals encouraged
April 11, 2017Manufacturing and Production Egypt, India, Sun Pharma
India and Egypt have been tentatively trying to build economic links for the last few years, with a particular focus …
NICE turns down BMS’ Opdivo for head and neck cancer
April 11, 2017Manufacturing and Production, Sales and Marketing BMS, NICE, opdivo
Bad news for Bristol-Myers Squibb as NICE chooses not to recommend its immunotherapy drug Opdivo (nivolumab) for use in head …
Bioverativ installs new EVP of R&D
April 10, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing bioverativ
Bioverativ, a biotech company that develops therapies for rare blood disorders, announced the appointment of Tim Harris as Executive Vice …
FDA approves first two antiviral hep C drugs for paediatric patients
April 10, 2017Sales and Marketing FDA, harvoni, hepatitis C, sovaldi
The FDA has given the go-ahead for two hepatitis C treatments for use in young and adolescent patients: Sovaldi (sofosbuvir) …
Virus fixes DNA mutations for possible hearing loss therapy
April 10, 2017Research and Development, Sales and Marketing Ear, deafblindness, hearing loss, inner hair
Researchers at the Medical School at Harvard and MedUni Vienna’s Department of Ear, Nose and Throat Diseases have managed to …
EMA green lights Actelion’s drug after patient deaths scare
April 10, 2017Sales and Marketing Actelion, Johnson & Johnson, Uptravi
The EMA has ruled that the five patient deaths that occurred in February of this year were not directly related …
Roche’s lung cancer drug beats Pfizer rival in study
April 10, 2017Research and Development, Sales and Marketing Alecensa, Roche
Roche has announced that its drug Alecensa (alectinib) succeeded in meeting its primary endpoint in a Phase 3 trial assessing …
Fresenius confirms takeover talks with Akorn
April 10, 2017Sales and Marketing Akorn, Fresenius
Fresenius, Europe’s largest publicly traded healthcare provider, has engaged in discussions with Akorn, a pharmaceutical generics drugmaker, with a view …
Novartis takes on dry-eye market with drug in-licensing move
April 7, 2017Medical Communications, Sales and Marketing Lubris, Novartis, dry eye
Novartis has announced that its eyecare-focused division Alcon has in-licensed dry-eye drug ECF843 from US firm Lubris for ophthalmic indications …
Old antibiotic nears new FDA approval after positive trials
April 7, 2017Medical Communications, Research and Development Pfizer, Zavante, Zolyd, antibiotic
Zavante, a biotech company based in San Diego, has unveiled positive results from a recent Phase II/III trials that could …
Top Ten most popular articles on Pharmafile.com this week
April 7, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing top ten
It’s Friday, and medical device recalls have been the flavour of the week, with both GSK and Mylan having to …
Clinical trial shows yoga negates side-effects of prostate cancer treatment
April 7, 2017Medical Communications prostate cancer, prostate treatment, yoga
Men who are treated for prostate cancer display side-effects of treatment by radiation that can often seriously disrupt their personal …
Latest content
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
